Enallylpropymal

In this article we will explore in depth the topic of Enallylpropymal, a topic that has aroused the interest and curiosity of people from different fields. From its impact on society to the implications it has on our daily lives, Enallylpropymal is a topic that deserves to be analyzed in detail. Along these lines, we will delve into its origins, its evolution over time and the various perspectives that exist around it. Whether you are an expert in the field or simply someone interested in learning more about it, this article is intended to offer a complete and enriching overview of Enallylpropymal.

Enallylpropymal
Clinical data
Other namesEnallylpropymal
ATC code
  • none
Identifiers
  • (RS)-1-Methyl-5-allyl-5-isopropyl-1,3-diazinane-2,4,6-trione
CAS Number
PubChem CID
ChemSpider
UNII
ECHA InfoCard100.015.876 Edit this at Wikidata
Chemical and physical data
FormulaC11H16N2O3
Molar mass224.260 g·mol−1
3D model (JSmol)
ChiralityRacemic mixture
  • O=C1NC(=O)N(C)C(=O)C1(C(C)C)CC=C
  • InChI=1S/C11H16N2O3/c1-5-6-11(7(2)3)8(14)12-10(16)13(4)9(11)15/h5,7H,1,6H2,2-4H3,(H,12,14,16)
  • Key:AXJXURWWUFZZKN-UHFFFAOYSA-N
  (verify)

Enallylpropymal (Narconumal) is a barbiturate derivative developed by Hoffman la Roche in the 1930s. It has sedative and hypnotic effects and is considered to have a moderate abuse potential.

References

  1. ^ US 2072829, Schnider O, "N-Methyl-5,5-allylisopropylbarbituric acid", issued 2 March 1937, assigned to Hoffmann-La Roche Inc. 
  2. ^ Eddy NB, Halbach H, Isbell H, Seevers MH (1965). "Drug dependence: its significance and characteristics". Bulletin of the World Health Organization. 32 (5): 721–33. PMC 2555251. PMID 5294186.